Orbus Therapeutics Inc. is a late-stage, private biopharmaceutical company that is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The Company's lead product candidate, eflornithine, is being evaluated in a pivotal Phase 3 clinical trial in patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer.
Looking for a particular Orbus Therapeutics, Inc. employee's phone or email?
The Orbus Therapeutics, Inc. annual revenue was $5 million in 2026.
Noymi Yam is the VP, Chief Scientific Officer of Orbus Therapeutics, Inc..
3 people are employed at Orbus Therapeutics, Inc..
Orbus Therapeutics, Inc. is based in Palo Alto, California.
The NAICS codes for Orbus Therapeutics, Inc. are [541714, 541, 5417, 54, 54171].
The SIC codes for Orbus Therapeutics, Inc. are [87, 873].